Antenatal Bartter's syndrome: Why is this not a lethal condition?

Detlef Böckenhauer*, M. Cruwys, R. Kleta, L. F. Halperin, P. Wildgoose, T. Souma, N. Nukiwa, S. Cheema-Dhadli, C. K. Chong, K. S. Kamel, M. R. Davids, M. L. Halperin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


There are four themes in this teaching exercise for Professor McCance. The first challenge was to explain how a premature infant with Bartter's syndrome could survive despite having such a severe degree of renal salt wasting. Second, the medical team wanted to know why there was such a dramatic decrease in the natriuresis in response to therapy, despite the presence of a permanent molecular defect that affected the loop of Henle. Third, Professor McCance was asked why this patient seemed to have a second rare disease, AQP2 deficiency type of nephrogenic diabetes insipidus. The fourth challenge was to develop a diagnostic test to help the parents of this baby titrate the dose of indomethacin to ensure an effective dose while minimizing the likelihood of developing nephrotoxicity. The missing links in this interesting story emerge during a discussion between the medical team and its mentor.

Original languageEnglish (US)
Pages (from-to)927-942
Number of pages16
Issue number12
StatePublished - 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Antenatal Bartter's syndrome: Why is this not a lethal condition?'. Together they form a unique fingerprint.

Cite this